Form 4: Macrogenics Director Reports Stock Transactions

David C. Stump, a Director at Macrogenics Inc., reported transactions involving restricted stock units and stock options.

Summary

• David C. Stump, a Director at Macrogenics Inc. (MGNX), reported several transactions on May 18-19, 2026.
• He acquired 3,750 shares of common stock through the vesting of restricted stock units (RSUs).
• An additional 3,750 RSUs were acquired on May 19, 2026, with vesting scheduled for one year after the grant date or the day prior to the next annual meeting.
• Mr. Stump also acquired 22,000 stock options with an exercise price of $4.52, which vest monthly starting one month from the grant date and expire on May 19, 2036.
• Following these transactions, Mr. Stump beneficially owns 14,750 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine stock option and RSU grants and vesting for a director, which are typical compensation and incentive mechanisms.

Positives

• Director David C. Stump acquired 3,750 shares of common stock through the vesting of RSUs, indicating an increase in his direct ownership.
• The acquisition of 22,000 stock options suggests potential future upside and alignment with the company's performance.
• The RSUs acquired on May 19, 2026, are set to vest, further increasing potential direct ownership.

Negatives

• The filing details the disposition of 3,750 shares of common stock, though the context (e.g., sale) is not explicitly stated in the provided data.

Future Outlook

The filing indicates that 3,750 RSUs will vest one year after the grant date or the day prior to the next annual meeting, and stock options will vest monthly over a period starting one month from the grant date.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These transactions can offer insights into management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may signal confidence, but the transactions themselves are part of standard compensation and do not inherently alter the company's fundamental value.
• Employees: The stock option grants and RSU vesting are part of the executive compensation structure, aligning management interests with shareholder value.
• Management: The transactions reflect the ongoing compensation and incentive plans for key personnel.

Next Steps

• Vesting of 3,750 RSUs on or before the day prior to the next annual meeting.
• Monthly vesting of 22,000 stock options beginning one month from the grant date.

Key Dates

Keywords

Macrogenics Inc., MGNX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Director Transactions